l-yl-3-methoxypropan-2-ol; NSC-26 1037;  Ro 07-0582, Roche Laboratories), is currently under clinical investigation at a number of radiotherapy centres. In previous clinical studies (Dische et al., 1977; Urtasun et al., 1977; Wiltshire et al., 1978) plasma MIS concentrations have been determined and this was found to be important for 2 reasons. Firstly, the radiation enhancement ratio for hypoxic cells is dependent upon MIS concentration (Asquith et al., 1974) . Although reported tumour concentrations in man vary from 12-107°, of the corresponding plasma concentration, peak values of 70-100% are usual (Gray et al., 1976; Dische et al., 1977; Urtasun et al., 1977; Wiltshire et al., 1978) . Thus the plasma MIS concentration usually gives a reasonable estimate of the drug concentration in the tumour, and hence the theoretical radiation-enhancement ratio. Secondly, the neurotoxicity of MIS is dependent upon the total tissue exposure, which can be estimated from the area under the curve of plasma concentration against time (Dische et al., 1977) .
However, serial blood sampling can be troublesome to the patient and a non-invasive technique would be advantageous. Estimation of salivary drug concentrations has recently proved useful for a variety of drugs (see reviews by Speirs, 1977; Horning et al., 1977) including methotrexate (Steele et al., 1978) . We have therefore investigated the feasibility of monitoring the salivary concentration of MIS in 10 patients with neoplastic disease under treatment.
M1ETHODS
Clinical details of the patients are summarized in Table I . All gave their informed consent. MIS was given orally at about 10 a.m. after a light breakfast. The drug was administered in 500 mg capsules (Roche Laboratories) so as to give doses as close as possible to 0-5 g/m2 (low dose), 1U g/m2 (intermediate dose) or 3 g/m2 (high dose).
Blood samples (10 ml) were taken by Concentrations of MIS and its 0-demethylated metabolite (1-(2-nitroimidazol-1-yl)-2,3-propandiol; Ro 05-9963, Roche Laboratories) in plasma and saliva were determined by reverse-phase high-performance liquid chromatography (HPLC) as described previously for plasma (Workman et al., 1978 (Crowe & Crowe, 1969) The saliva/plasma nitroimidazole concentration ratio at a given time was the saliva concentration divided by the corresponding plasma concentratioin.
RESULTS
Relationship between plasma and salina MIS concentration Fig. I shows plasma and saliva MIS concentrations plotted on a logarithmic scale against time on a linear scale for 3 typical patients receiving doses of 0-5, 1-5 and 3-0 g/m2 MIS respectively. It may, be seen that saliva concentrations were similar to, though generally rather lower than, the corresponding plasma concentrations. The linear relationship between plasma and saliva MIS concentration is illustrated in Fig. 2 , which shows the complete data from all 1 0 patients (r = 0 93, P < 0 001).
Saliva/plasma MIS r-atio
In general the intra-patient saliva/ plasma concentration ratios exhibited very little variation, as shown bv the small standard errors for individual patients (Table II) . There was no change in this ratio with time after drug administration, indicating rapid equilibration between the 2 fluids. The atypically large standard error observed for Patient R.G. is attributed to the fact that the saliva samples from this patient were contaminated with sputum to a varying degree. Peak MIS concentration Peak saliva MIS concentrations were generally rather lower than those seen in the plasma (Table II) . However, the times at which the peak concentrations were observed were very similar. The median peak time for both plasma and saliva was 2 h and the interquartile range was I h in both. Area under the curve The AUC values for plasma and saliva MIS concentration are given in Table II (Table II) .
Systemic drug clearance
In some cases systemic drug clearance is preferred to plasma half-life as a measure of the efficiency of drug removal from the body (Perrier & Gibaldi, 1974; Wilkinson & Shand, 1975 . The MIS 0-demethylated metabolite Ro 05-9963 was detected in the saliva and plasma of all 10 patients (see Fig. 4) . However, the concentrations observed for patients receiving the lowest dose (0 5 g/m2) were all lower than 1 5 ,ug/ml. The precision of the HPLC method decreases at concentrations below 2 ,ug/ml, so these data are not presented. Nevertheless, the general pattern was similar to that seen at the higher doses. Saliva/plasma Ro 05-9963 concentration ratios and AUC values for the patients receiving 1.5 and 3 0 g/m2 are presented in Table  III . The mean z s.d. of the mean saliva/ plasma ratios for the 7 patients receiving the intermediate and high doses was 0-76 ± 0-21 and th'e coeff. variation was 28%o.
There was a tendency for peak saliva metabolite concentrations to be seen later than peak plasma concentrations. For the 7 patients receiving high and intermediate doses the median peak times for plasma and saliva were 6 and 12 h respectively (the interquartile range was 6 h in both cases).
Tumour concentrations
Tumour concentrations were determined for 3 of the patients receiving the highest MIS dose (3 g/m2). Panel A in Fig. 4 shows the concentrations of MIS and Ro 05-9963 in serial biopsy specimens of a skin metastasis in a patient (C.L.) with an undifferentiated lung carcinoma, together with corresponding plasma and saliva data. Two types of saliva collection were made at 1, 2, 4 and 6 h: a normal sample followed by a sample taken after salivary flow was stimulated with lemon juice. It can be seen that normal and stimulated saliva had essentially the same MIS concentration.
The shapes of the concentration vs time plots for tumour, plasma and saliva were very, similar. The half-life for the elimina- tion of MIS from the tumour was 7-8 h (5.9-11*6 h), which compares with values of 9-2 h (8.6-10 0 h) for plasma and 12-7 h (11 0-15.1 h) for saliva. The estimated AUC for tumour MIS was 1154 jtg/ml/h which represents 72% of the plasma AUC and 820% of the saliva AUC (see Table   II ). The mean i s.e. for the tumour/ plasma MIS ratio was calculated to be 0 73 + 0-06 (n -4) and the tumour/ saliva (unstimulated) ratio was 0-81 ± 0 15 (n = 4). Ro 05-9963 was only detected at 4 and 12-25 h and the mean tumour/plasma and tumour/saliva ratios were 0 75 and 0-76 respectively.
Panel B in Fig. 4 depicts the concentrations of MIS and Ro 05-9963 in serial biopsy specimens of an abdominal-wall metastasis in a patient (A.T.) with a recurrent colon adenocarcinoma. The estimated AUC for tumour MIS was 1205 Htg/ml/h which represents 60% of the plasma AUC and 64% of the saliva AUC (see Table II ).
The half-life for elimination of MIS from the tumour was 12-2 h (10-4-14 7 h) which compares with values of 16-2 h (14-0-19-4 h) for plasma and 17-7 h (13.4-26-1 h) for saliva. The mean ± s.e. for the tumour/plasma MIS ratio was 0-64 ± 0 07 (n -4) and for the tumour/saliva ratio 0 73 ± 0 11 (n -4). Ro 05-9963 was detected in the tumour at 2, 4, 12 and 24 h and the mean tumour/plasma and tumour/saliva ratios (± s.e.) were 1-07 ± 0 28 (n = 4) and 1-03 ± 0 17 (n = 4) respectively. Table IV summarizes the results obtained for serial biopsy specimens of a skin metastasis in a patient (E.E.) with an undifferentiated bronchial carcinoma, together with corresponding plasma and saliva data. In this case the tumour, plasma and saliva nitroimidazole concentrations were similar at 2 and 4 h, but at 12 and 24 h tumour concentrations were considerably higher than in plasma and saliva.
DISCUSSION
The present studies have demonstrated a good linear correlation between the concentrations of MIS in plasma and mixed saliva. Intra-patient differences in saliva/plasma MIS ratio were small and did not vary appreciably with time after drug administration. However, some interpatient variation was noted, with saliva/ plasma ratios ranging from 0 59 to 1.11. On the other hand, with the exception of 2 patients, the mean saliva/plasma ratios were all greater than 0O8.
A number of factors may be involved in determining saliva/plasma drug ratios. These include the mol. wt of the drug (or membrane porosity); the pKa, partition coefficient and protein-binding properties of the drug; plasma and saliva pH; salivary flox rate; the state of oral hygiene; and the nature and concentration of plasma and saliva constituents, particularly proteins and oral debris.
Some of these factors have been reviewed briefly by Schanker (1964) and Speirs (1977) .
The physicochemical properties of MIS are such that good penetration through cell membranes would be expected. Firstly, MIS is a comparatively small molecule (mol. wt 201). Secondly, on the basis of previous studies on related nitroimidazoles (Gallo et al., 1964) , it is clear that MIS will be un-ionized in the physiological pH range. Thirdly, the octanol/ water partition coefficient for MIS at pH 7*4 is 0 43 , which indicates that the drug is somewhat lipophilic. The intra-patient saliva/plasma misonidazole ratios were independent of plasma MIS concentration, which suggests that the transfer of the drug from plasma to saliva probably occurs by passive diffusion.
Salivary flow rate is a possible factor affecting saliva/plasma ratios, but the present studies suggested that this was not so for MIS.
Salivary pH is not constant, but tends to be lower than that of the plasma. In a series of fresh saliva samples from 10 laboratory staff, we found that the pH varied from 6-4 to 7-5 (mean 6.9).
Similar findings have been reported by others (Kostlin & Rauch, 1957; Mason & Chisholm, 1975 & Speirs, 1976; Speirs, 1977) . The various secretions show some differences in composition, and differences between gingival fluid and the glandular secretions are particularly marked (Mason & Chisholm, 1975) . Moreover, the concentrations of certain antibiotics are higher in gingival fluid than in glandular saliva (MacFarlane, et al., 1974) . Adsorption of drugs by oral debris may also affect their concentration in mixed saliva (Paxton, et al., 1976) .
In view of the usefulness of pharmacokinetic determinations for predicting the possible toxic and therapeutic effects of MIS in individual patients (Dische et al., 1977; Wiltshire et al., 1978) W\Te have speculated that at least part of the inter-patient variations in saliva/ plasma ratios may be due to the variable composition of mixed saliva. To avoid this problem, Stephen & Speirs (1976) recommended the collection of individual components of mixed saliva, for which techniques are available (Mason & Chisholm, 1975; Stephen & Speirs, 1976) . However, in using these methods much of the simplicity of mixed-saliva sampling would be lost.
In contrast to our experience with (Stephen & Speirs, 1976 ). An important disadvantage of saliva sampling is that it is unsuitable for oral medications other than capsule formulations, because only the latter prevent direct contamination of saliva by the drug (Speirs et al., 1971; Graham & Rowland, 1972) . MIS has previously been supplied in both tablet and capsule formulations. Moreover, because of the large doses involved, some patients prefer to take the drug as a solution. In the present study we have used capsules only, and we would not recommend the use of saliva sampling for other oral formulations.
To attempt to predict the possible therapeutic effect of MIS, the concentration of radiosensitizing species in the tumour must be known. In the present study we were able to determine tumour concentrations of MIS and Ro 05-9963 as well as data for plasma and saliva, in 3 patients. In general, the tumour nitroimidazole concentrations were within the range 50-100% of the corresponding plasma concentrations. This is in agreement with previous findings (Dische et al., 1977; Wiltshire et al., 1978) . However, in one patient, tumour levels at 12 and 24 h were considerably higher than those in plasma. Comparison of tumour, plasma and saliva data for this small sample of patients suggests that saliva data are at least as good as plasma data for predicting tumour nitroimidazole concentrations.
